Olympus Companions has $4 billion to take a position after the center market personal fairness agency wrapped up fundraising for its newest flagship fund. The agency mentioned Wednesday that its eighth pool got here in at $3.5 billion, and jumped to $4 billion with the inclusion of coinvestments from its LPs and anticipated reinvestments, in line with a March 26 letter to Olympus traders. Olympus had set a $4 billion onerous cap for Fund VIII, the utmost the fund was permitted to lift from traders.
Olympus spent roughly a 12 months advertising and marketing for its eighth pool, which raised 15% greater than its prior fund. Olympus Development Fund VII collected $3.04 billion in late 2017.
Earlier this month, Fortune reported that Olympus fund VIII had raised $2.87 billion.
Olympus is the PE agency from Chairman and CEO Rob Morris, who can also be its founder. The agency invests in enterprise providers, meals providers, client merchandise, healthcare providers, monetary providers, industrial providers and manufacturing. Since launching in 1988, Olympus has raised $12 billion in capital. The agency has additionally returned $6 billion to traders over the previous three years, together with $3 billion in 2024, Fortune has reported.
Morris, within the letter, mentioned the tariff-driven coverage of the Trump administration, which has prompted rampant inventory market volatility, and fears of a recession. Morris mentioned personal fairness managers ought to do their greatest to keep away from the “incoming missiles” of tariffs. For companies with a provide chain closely depending on tariff targets, he suggested diversifying to safer geographies or pursuing tariff exempted alternate options. “There are a lot of different tactical strikes, however no foolproof plan to fully keep away from the financial storm a commerce warfare might ignite,” Morris wrote within the letter.
Fund VIII started investing in January and has to date accomplished two transactions. In January, Olympus acquired Accelevation, a supplier of infrastructure services to the information middle market, for $455 million. The PE agency additionally scooped up generic drug maker PAI Pharma for $605 million in February. The offers had been “the quickest Olympus has bought two investments on the creation of a Fund,” in line with the letter.
This story was initially featured on Fortune.com
